AL
Alnylam Pharmaceuticals
ALNY · NASDAQ
$266.11 +3.13% (+$8.09)
1M +21.40%
Market Cap $35.4B
P/E Ratio 43.80x
Div. Yield -
ROE 93.61%
Bulios Fair Price
$164.14
38.3% downside
Current Price
$266.11
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ALNY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
1 /100
Expensive EV/EBITDA 30.38x
P/S 7.37x
P/B 26.14x
Growth
100 /100
Growing Rev. growth 52.98%
FCF growth N/A
Book val. growth N/A
Profitability
86 /100
Strong Net margin 16.82%
Op. margin 20.81%
FCF margin 11.29%
Quality
96 /100
Excellent ROE 93.61%
ROA 14.54%
Asset turnover 0.86x
Debt
75 /100
Low Current ratio 3.05x
Int. coverage 3.37x
Net debt/EBITDA -0.38x
Stability
19 /100
Unstable Rev. volatility 28.11%
EPS volatility 91.31%
Profitable years 1
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ALNY
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Yvonne L. Greenstreet
Employees
2,500
Headquarters
Cambridge
Upcoming events
29 OCT
Earnings
Upcoming earnings report